University of Pittsburgh study finds malaria drug could combat chemotherapy-resistant head and neck cancers

Robert L. Ferris named executive director of UNC Lineberger—with an additional job as chief of oncology services

Robert L. Ferris, a head-and-neck surgeon and an expert in cancer immunotherapy was named the executive director of UNC Lineberger Comprehensive Cancer Center and the chief of oncology services at UNC Health.

Proton therapy demonstrates advantages for head and neck cancer in phase III trial preliminary data

According to preliminary data from a multi-institution phase III trial led by researchers at MD Anderson Cancer Center, intensity modulated proton therapy achieved similar clinical outcomes and offered significant patient benefits when compared to traditional intensity modulated radiation therapy as part of chemoradiation treatment for patients with oropharyngeal cancer.

June 07, 2024

Vol.50 No.23

Clinical Roundup

Setanaxib combination improves PFS and OS in SCCHN in phase II trial

A phase II trial evaluating setanaxib, Calliditas Therapeutics AB’s lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with squamous cell carcinoma of the head and neck shows positive topline results.

May 10, 2024

Vol.50 No.19

Clinical Roundup

Subgroup analysis focuses on P-BCMA-ALLO1 allogeneic CAR T in multiple myeloma

Data from a subset of patients in an ongoing phase I study of Poseida Therapeutics’s lead program P-BCMA-ALLO1 showed that three of the five (60%) patients with relapsed/refractory multiple myeloma who had progressed following BCMA-targeted therapy achieved clinical responses with P-BCMA-ALLO1. In addition, this investigational treatment was well-tolerated.

April 19, 2024

Vol.50 No.16

In Brief

Monica Baskin named deputy director of UPMC Hillman

Monica L. Baskin, an expert in health equity, was named deputy director of UPMC Hillman Cancer Center.

February 16, 2024

Vol.50 No.07

Clinical Roundup

Community cancer care linked with poorer outcomes for some head/neck cancers

Care for patients with human papillomavirus (HPV)-related squamous cell cancers of the oropharynx (an area in back of the throat) is shifting toward community cancer centers, but patients treated in this setting may be less likely to survive, according to new research by investigators from the Johns Hopkins Kimmel Cancer Center and its Head and Neck Cancer Center.

January 05, 2024

Vol.50 No.01

University of Pittsburgh study finds malaria drug could combat chemotherapy-resistant head and neck cancers

YOU MAY BE INTERESTED IN

Robert L. Ferris named executive director of UNC Lineberger—with an additional job as chief of oncology services

Proton therapy demonstrates advantages for head and neck cancer in phase III trial preliminary data

Setanaxib combination improves PFS and OS in SCCHN in phase II trial

Subgroup analysis focuses on P-BCMA-ALLO1 allogeneic CAR T in multiple myeloma

Monica Baskin named deputy director of UPMC Hillman

Community cancer care linked with poorer outcomes for some head/neck cancers

Renew today!

Subscriber content

Login